Answers are grounded in this paper and cite their sources.
INTRODUCTION The α‐synuclein (αSyn) seed amplification assay (αSyn‐SAA) is an accurate tool to detect αSyn seeds in patients with Parkinson's disease (PD). However, a minority of clinically diagnosed PD patients are negative for αSyn. METHODS The αSyn‐SAA was performed in cerebrospinal fluid (CSF) of individuals with PD ( n = 93), multiple system atrophy (MSA, n = 26), progressive supranuclear palsy (PSP, n = 18), corticobasal syndrome ( n = 3), and healthy controls ( n = 29). RESULTS The αSyn‐SAA detected αSyn in 90% of PD and 81% of MSA patients, while exhibiting high specificity (97%). SAA– PD patients had a distinct phenotype compared to SAA+ PD, including a marked postural instability/gait disorder ( P = 0.002), impaired episodic memory, and lower CSF amyloid beta 42 ( P = 0.03). SAA+ PSP also displayed distinctive traits. DISCUSSION A negative αSyn‐SAA in PD is associated with a distinct phenotype and pathological findings suggesting that these patients may have a motor subtype of Alzheimer's disease. This could influence future clinical trials. Highlights The α‐synuclein seed amplification assay (αSyn‐SAA) is a robust assay. αSyn‐SAA–negative Parkinson's disease shows a distinct motor–cognitive phenotype. Autopsy showed Alzheimer's disease (AD) pathology in parkinsonian diseases. AD stands as a major clinical confounder for the diagnosis of movement disorders.
No takes yet. Share an insight, caveat, or question.
Gomes et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: